Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Hydroxyurea

Brand Name: Droxia, Hydrea, hydroxycarbamide

Generic Name: Hydroxyurea

Drug Class: Antineoplastics, Antimetabolite

What Is Hydroxyurea and How Does It Work?

Hydroxyurea is an antineoplastic (anti-cancer) agent used to treat melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and primary squamous cell (epidermoid) carcinomas of the head and neck.

Hydroxyurea is available under the following different brand names: Droxia, Hydrea, and hydroxycarbamide.

Dosages of Hydroxyurea:

Dosage Forms and Strengths

Capsules

  • 200 mg
  • 300 mg
  • 400 mg
  • 500 mg

Dosage Considerations – Should be Given as Follows:

Solid Tumors

  • Intermittent Therapy: 80 mg/kg orally every 3 days, OR
  • Continuous Therapy: 20-30 mg/kg orally once/day

Head and Neck Tumors

Concomitant therapy with irradiation

  • 80 mg/kg orally every 3 days
  • Begin 7 days prior to initiation of irradiation

Head and Neck Tumors

  • 80 mg/kg orally every 3 days
  • Begin 7 days prior to initiation of irradiation

Chronic Myelocytic Leukemia, Resistant

  • Continuous Therapy: 20-30 mg/kg orally once/day

Sickle Cell Disease

  • Start: 15 mg/kg/day as single dose; monitor patient's blood count every two weeks
  • Titrate by 5 mg/kg/day every 12 weeks
  • Dose is not increased if blood counts are between acceptable range and toxic
  • Not to exceed 35 mg/kg/day
  • Discontinue therapy until hematologic recovery if blood counts are considered toxic; may resume treatment after reducing dose by 2.5 mg/kg/day from dose associated with hematological toxicity

Thrombocythemia, Essential (Off-label)

HIV, Adjunct Treatment (Off-label)

  • 500 mg orally twice daily
  • Use with antiretrovirals

Psoriasis (Off-label)

  • 1000-1500 mg/day orally once or twice daily

Other Information

  • Monitor: complete blood counts (CBC)

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

What Are Side Effects Associated with Using Hydroxyurea?

Side effects of hydroxyurea include:

Serious side effects of hydroxyurea include:

  • Anemia
  • Myelosuppression
  • Leukemia

Postmarketing side effects of hydroxyurea reported include:

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

What Other Drugs Interact with Hydroxyurea?

If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.

Severe interactions of hydroxyurea include:

Serious interactions of hydroxyurea include:

  • human papillomavirus vaccine, bivalent
  • human papillomavirus vaccine, nonavalent
  • human papillomavirus vaccine, quadrivalent
  • tofacitinib

Hydroxyurea has moderate interactions with at least 115 different drugs.

Hydroxyurea has no known mild interactions with other drugs.

This information does not contain all possible interactions or adverse effects. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns or for more information about this medicine.

What Are Warnings and Precautions for Hydroxyurea?

Warnings

  • Hydroxyurea therapy may be complicated by severe, sometimes life-threatening, adverse effects; because of this, it should be administered under the supervision of a physician experienced in the use of this medication
  • Hydroxyurea is mutagenic and clastogenic, and causes cellular transformation to a tumorigenic phenotype, and is thus unequivocally genotoxic and a presumed trans-species carcinogen that implies a carcinogenic risk to humans; advise sun protection and monitor patients for malignancies
  • Hydroxyurea may cause severe myelosuppression; do not administer if bone marrow function is markedly depressed; monitor blood counts at baseline and throughout treatment; interrupt treatment and reduce dose as necessary
  • In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemias have been reported
  • It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patients' underlying disease
  • The physician and patient must very carefully consider the potential benefits relative to the undefined risk of developing secondary malignancies
  • This medication contains hydroxyurea
  • Do not take Droxia, Hydrea, or hydroxycarbamide if you are allergic to hydroxyurea or any ingredients contained in this drug

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.

Contraindications

Effects of Drug Abuse

  • None

Short-Term Effects

  • See "What Are Side Effects Associated with Using Hydroxyurea?"

Long-Term Effects

  • See "What Are Side Effects Associated with Using Hydroxyurea?"

Cautions

  • Caution in renal impairment, coadministration with myelosuppressive agents.
  • Low white blood cell counts (leukopenia and neutropenia) commonly occur; low platelet counts (thrombocytopenia) and anemia are less common; hematologic toxicity is reversible.
  • Do not change dose too frequently.
  • Not recommended in sickle cell anemia if neutrophils less than 2,000/mm³, platelets less than 80,000/mm³, hemoglobin less than 4 g/dL, or reticulocytes less than 80,000/mm³ when hemoglobin less than 9 g/dL.
  • Increased risk of hepatotoxicity, which may be fatal, may occur, particularly in combination with didanosine and stavudine.
  • Risk of cutaneous vasculitic toxicities in patients with myeloproliferative disorders, especially with history of or concurrent interferon therapy.
  • Discontinue if white blood cell count is less than 2500/mm³ and/or platelets less than 100,000/mm³.
  • Erythrocyte abnormalities reported; self-limiting megaloblastic erythropoiesis reported early in treatment, unrelated to vitamin B12 or folic acid deficiency.
  • Hyperuricemia may occur; adequate hydration, dosage adjustment, or initiation of uricosuric agents may be necessary.
  • Interferes with analytical analyses of the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid and lactic acid, rendering falsely elevated results.
  • Advise females of reproductive potential to use effective contraception during and after treatment for at least 6 months after therapy; advise males of reproductive potential to use effective contraception during and after treatment for at least 1 year after therapy.
  • Avoid use of live vaccine; concomitant use with a live virus vaccine may potentiate replication of virus and/or may increase adverse reaction of vaccine because normal defense mechanisms may be suppressed; may result in severe infection; antibody response to vaccine may be decreased.

Pregnancy and Lactation

  • Use hydroxyurea during pregnancy only in LIFE-THREATENING emergencies when no safer drug is available. There is positive evidence of human fetal risk. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea for at least 6 months after therapy; advise males of reproductive potential to use effective contraception during and after treatment for at least 1 year after therapy.
  • Hydroxyurea is excreted in breast milk, do not nurse.
References
Medscape. Hydroxyurea.
https://reference.medscape.com/drug/droxia-hydrea-hydroxyurea-342100
RxList. Hydrea.
https://www.rxlist.com/hydrea-side-effects-drug-center.htm
CONTINUE SCROLLING FOR RELATED SLIDESHOW

Health Solutions From Our Sponsors